Pharmaceutical Industry in Ghana and Nigeria

A Ripe Business Opportunity for Big Pharma and Generic Pharma Companies

Regular Price: USD 4,950

Special Price USD 4,455

10% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,455

PAY BY INVOICE

Be the first to review this product

The pharmaceutical industry in Ghana and Nigeria is forecast to represent a combined business opportunity of over $3 billion by 2018, propelled by a convergence of changing economic profiles, increased healthcare spending and investment, and increasing incidence of chronic diseases. Market segmentation is done based on products (OTC, generic, and branded) as well as therapeutic areas (anti-infectives, cardiovascular, diabetes, oncology, respiratory, and CNS). This study provides a detailed analysis that includes market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the pharmaceutical industry in Ghana and Nigeria.

Table of Contents

Executive SummaryKey FindingsKey Findings (continued)Scope and SegmentationMarket Segmentation Market Segmentation (continued)Key Questions This Study Will AnswerMarket Engineering MeasurementsCEO’s PerspectiveKey Companies to WatchExecutive Summary—Three Big PredictionsMarket OverviewMarket SegmentationMarket Segmentation (continued)Segmentation by Tiers of CompetitionSegmentation by Tiers of Competition (continued)Competitive PlaybookNew Market OpportunitiesNew Market Opportunities (continued) Key Merger, Acquisition, and Partnership AssessmentKey Merger, Acquisition, and Partnership Assessment (continued)Drivers and Restraints—Total Pharmaceutical Industry in Ghana and NigeriaMarket DriversDrivers ExplainedDrivers Explained (continued)Drivers Explained (continued)Drivers Explained (continued)Market RestraintsRestraints ExplainedRestraints Explained (continued)Restraints Explained (continued)Restraints Explained (continued)Restraints Explained (continued)Market Impact of Key Drivers and RestraintsForecasts and Trends—Total Pharmaceutical Industry in Ghana and NigeriaMarket Engineering MeasurementsForecast Assumptions and DefinitionsRevenue ForecastRevenue Forecast DiscussionRevenue Forecast Discussion (continued)Per Cent Revenue Forecast by RegionRevenue Forecast by RegionGhana & Nigeria—Therapeutic Segment Growth AnalysisProcurement Process Ghanaian Pharmaceutical Industry OverviewGhanaian Pharmaceutical Industry OverviewGhanaian Pharmaceutical Industry Overview (continued)Ghana—Health ProfileGhana—MalariaGhana—Malaria (continued)Ghana—Malaria (continued)Ghana—Tuberculosis (TB)/HIVGhana—Tuberculosis (TB)/HIV (continued)Ghana—Tuberculosis (TB)/HIV (continued)Ghana—Non-communicable Diseases (NCDs)Ghana—Non-communicable Diseases (continued)Ghana—Non-communicable Diseases (continued)Ghana—Non-communicable Diseases (continued)Ghanaian Pharmaceutical Industry—Forecasts and TrendsGhanaian Pharmaceutical IndustryGhanaian Pharmaceutical Industry—Market Engineering MeasurementsGhanaian Pharmaceutical Industry—Revenue ForecastGhanaian Pharmaceutical Industry—Revenue Forecast DiscussionGhanaian Pharmaceutical Industry—Revenue Forecast Discussion (continued)Ghana—Per Cent Revenue Forecast by Product Segment Ghana—Per Cent Revenue Forecast by Therapeutic SegmentOTC Pharmaceuticals Segment—Revenue ForecastOTC Pharmaceuticals Segment—Revenue Forecast DiscussionGeneric Pharmaceuticals Segment—Revenue ForecastGeneric Pharmaceuticals Segment—Revenue Forecast DiscussionBranded Pharmaceuticals Segment—Revenue ForecastBranded Pharmaceuticals Segment—Revenue Forecast DiscussionAnti-infectives Segment—Revenue ForecastAnti-infectives Segment—Revenue Forecast DiscussionAnti-infectives Segment—Revenue Forecast Discussion (continued)Anti-infectives Segment—Revenue Forecast Discussion (continued)Cardiovascular Segment—Revenue ForecastCardiovascular Segment—Revenue Forecast DiscussionDiabetes Segment—Revenue ForecastDiabetes Segment—Revenue Forecast DiscussionRespiratory Segment—Revenue ForecastRespiratory Segment—Revenue Forecast DiscussionCNS Segment—Revenue ForecastCNS Segment—Revenue Forecast DiscussionOncology Segment—Revenue ForecastOncology Segment—Revenue Forecast DiscussionPricing AnalysisPricing Analysis (continued)Pricing Analysis (continued)Ghanaian Pharmaceutical Industry—SWOT AnalysisPESTLE AnalysisRegulatory AnalysisGhanaian Pharmaceutical Industry—Demand AnalysisGhanaian Pharmaceutical Industry—Procurement and Supply ManagementGhanaian Pharmaceutical Industry—Procurement and Supply Management (continued)Ghanaian Pharmaceutical Industry—DistributionGhanaian Pharmaceutical Industry—Distribution (continued)Ghanaian Pharmaceutical Industry—RetailGhanaian Pharmaceutical Industry—Demand AnalysisGhanaian Pharmaceutical Industry—Demand Analysis (continued)Ghanaian Pharmaceutical Industry—Competitive Landscape Competitive EnvironmentCompetitive Environment (continued)Ghanaian Pharmaceutical Industry—Competitor AnalysisMultinationalsGhanaian Pharmaceutical Industry—Competitor AnalysisGeneric CompaniesGhanaian Pharmaceutical Industry—Competitor AnalysisLocal ManufacturersGhanaian Pharmaceutical Industry—Competitor ProfileErnest Chemists LimitedGhanaian Pharmaceutical Industry—Competitor ProfileKinapharma LimitedGhanaian Pharmaceutical Industry—Competitor ProfilePhyto-Riker (GIHOC) Pharmaceutical LimitedGhanaian Pharmaceutical Industry—Competitor ProfileAyrton Drugs Manufacturing Company LimitedGhanaian Pharmaceutical Industry—Competitor ProfileKama Group LimitedNigerian Pharmaceutical Industry OverviewNigerian Pharmaceutical Industry OverviewNigerian Pharmaceutical Industry Overview (continued)Nigeria—Health ProfileNigeria—MalariaNigeria—Malaria (continued)Nigeria—Malaria (continued)Nigeria—Tuberculosis (TB)/HIVNigeria—Tuberculosis (TB)/HIV (continued)Nigeria—Tuberculosis (TB)/HIV (continued)Nigeria—Non-communicable Diseases (NCDs)Nigeria—Non-communicable Diseases (continued)Nigeria—Non-communicable Diseases (continued)Nigeria—Non-communicable Diseases (continued)Nigerian Pharmaceutical Industry—Forecasts and TrendsNigerian Pharmaceutical IndustryNigerian Pharmaceutical Industry—Market Engineering MeasurementsNigerian Pharmaceutical Industry—Revenue ForecastNigerian Pharmaceutical Industry—Revenue Forecast DiscussionNigerian Pharmaceutical Industry—Revenue Forecast Discussion (continued)Nigeria—Per Cent Revenue Forecast by Product Segment Nigeria—Per Cent Revenue Forecast by Product and Therapeutic SegmentOTC Pharmaceuticals Segment—Revenue ForecastOTC Pharmaceuticals Segment—Revenue Forecast DiscussionGeneric Pharmaceuticals Segment—Revenue ForecastGeneric Pharmaceuticals Segment—Revenue Forecast DiscussionBranded Pharmaceuticals Segment—Revenue ForecastBranded Pharmaceuticals Segment—Revenue Forecast DiscussionAnti-infectives Segment—Revenue ForecastAnti-infectives Segment—Revenue Forecast DiscussionAnti-infectives Segment Revenue—Forecast Discussion (continued)Anti-infectives Segment—Revenue Forecast Discussion (continued)Cardiovascular Segment—Revenue ForecastCardiovascular Segment—Revenue Forecast DiscussionDiabetes Segment—Revenue ForecastDiabetes Segment—Revenue Forecast DiscussionRespiratory Segment—Revenue ForecastRespiratory Segment—Revenue Forecast DiscussionCNS Segment—Revenue ForecastCNS Segment—Revenue Forecast DiscussionOncology Segment—Revenue ForecastOncology Segment—Revenue Forecast DiscussionPricing AnalysisPricing Analysis (continued)Nigerian Pharmaceutical Industry—SWOT AnalysisPESTLE AnalysisRegulatory AnalysisRegulatory Analysis (continued)Nigerian Pharmaceutical Industry—Demand AnalysisNigerian Pharmaceutical Industry—Procurement and Supply Management Nigerian Pharmaceutical Industry—Procurement and Supply Management (continued)Nigerian Pharmaceutical Industry—DistributionNigerian Pharmaceutical Industry—Distribution (continued)Nigerian Pharmaceutical Industry—Demand AnalysisGhanaian Pharmaceutical Industry—Demand Analysis (continued)Ghanaian Pharmaceutical Industry—Demand Analysis (continued)Nigerian Pharmaceutical Industry—Competitive Landscape Competitive EnvironmentCompetitive Environment (continued)Nigerian Pharmaceutical Industry—Competitor AnalysisMultinationalsNigerian Pharmaceutical Industry—Competitor AnalysisGeneric CompaniesNigerian Pharmaceutical Industry—Competitor AnalysisLocal ManufacturersNigerian Pharmaceutical Industry—Competitor ProfileEmzor Pharmaceutical Industries LimitedNigerian Pharmaceutical Industry—Competitor ProfileFidson Healthcare PLCNigerian Pharmaceutical Industry—Competitor ProfileMay & Baker Nigeria PLCNigerian Pharmaceutical Industry—Competitor ProfileEvans Medical PLCNigerian Pharmaceutical Industry—Competitor ProfileNigeria German Chemicals PLCKey Companies to Watch Key Companies to WatchThe Last WordThe Last Word—Three Big PredictionsThe Last Word—DiscussionThe Last Word—Discussion (continued)The Last Word—Discussion (continued)Legal DisclaimerAppendixMarket BackgroundImportant Market MetricsMarket Landscape and PricingDecision Support Database—Total Healthcare ExpenditureDecision Support Database—Total Healthcare Expenditure (continued)Decision Support Database—Public Healthcare ExpenditureDecision Support Database—Public Healthcare Expenditure (continued)Decision Support Database—Private Healthcare Expenditure Decision Support Database—Private Healthcare Expenditure (continued)Other Related Research Services List of Other Key Companies Included in this Research ServiceMarket Engineering MethodologyLearn More—Next Steps




Keyword1
pharmaceutical industry in ghana
Keyword2
pharmaceutical industry in nigeria
Keyword3
pharmaceutical industry in ghana

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.